Imunon Inc Stock Price, News & Analysis

IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, announced that CEO Dr. Stacy Lindborg will present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12, 2025, at 11:30 a.m. ET. The presentation will be an interactive online event allowing real-time investor questions. Investors can pre-register for the virtual presentation through the Virtual Investor Conferences site. Those unable to attend live can access an archived webcast later through IMUNON's website under the News & Investors section.

IMUNON (NASDAQ: IMNN) announced positive Phase 2 OVATION 2 Study results for IMNN-001 in treating newly diagnosed advanced ovarian cancer. The study showed significant improvements across multiple endpoints, with a median 13-month increase in overall survival (46 vs. 33 months) and a 3-month increase in progression-free survival (14.9 vs. 11.9 months) compared to standard care. The trial demonstrated enhanced efficacy when combined with PARP inhibitors, with median overall survival not reached after 5+ years versus 37 months for standard care. The drug showed particular promise in both HRP and HRD+ patients, including those with BRCA mutations. IMNN-001 doubled the complete/near-complete histopathological response rate (26.1% vs. 13.0%) and improved surgical outcomes with no macroscopic residual tumor (64.6% vs. 52.1%). The treatment maintained a favorable safety profile with no serious immune-related adverse events.

IMUNON (NASDAQ: IMNN) announced significant progress in their Phase 2 OVATION 2 Study for IMNN-001, their lead candidate for advanced ovarian cancer treatment. The study demonstrated remarkable results, showing a 13-month extension in median overall survival (46 vs. 33 months) compared to standard care. For patients receiving PARP inhibitors, median survival in the IMNN-001 arm exceeded 5 years. The drug showed enhanced efficacy in HRD+ and BRCA populations with a hazard ratio of 0.42, and maintained a favorable safety profile with manageable side effects. The company is now advancing to Phase 3 OVATION 3 Study with FDA support. IMNN-001, powered by the TheraPlas platform, represents a potential breakthrough as the first immunotherapy showing survival benefits in frontline ovarian cancer treatment with minimal side effects.

IMUNON (NASDAQ: IMNN) has closed a private placement offering priced at-the-market under Nasdaq rules, securing $3.25 million in initial gross proceeds through the sale of 7,222,223 shares of common stock (or pre-funded warrants) at $0.45 per share. The deal includes short-term warrants to purchase up to 14,444,446 additional shares, which if fully exercised, could generate up to $6.5 million in additional gross proceeds.

The warrants will be exercisable at $0.45 per share following stockholder approval and will expire three years from that date. H.C. Wainwright & Co. served as the exclusive lead placement agent, with Brookline Capital Markets as co-placement agent. The company plans to use the proceeds for working capital and general corporate purposes.

IMUNON (NASDAQ: IMNN) has been invited to present translational data from their Phase 2 OVATION 2 Study at the ESMO Gynaecological Cancers Congress 2025 in Vienna. The presentation will showcase biomarker analysis of IMNN-001, their DNA-mediated immunotherapy for advanced ovarian cancer. The study demonstrated significant results with 13-month improvement in overall survival and 3-month increase in progression-free survival. IMNN-001, based on TheraPlas® technology, is the first IL-12 immunotherapy showing survival benefits in frontline treatment of advanced ovarian cancer. The data will also be presented at the 2025 ASCO Annual Meeting and published in Gynecologic Oncology journal. The company has initiated their pivotal Phase 3 OVATION 3 Study, targeting approximately 40,000 women diagnosed with advanced ovarian cancer yearly in EU and 300,000 globally.

IMUNON (NASDAQ: IMNN) has secured a private placement offering priced at-the-market, raising $3.25 million initially through the sale of 7,222,223 shares of common stock (or pre-funded warrants) at $0.45 per share. The deal includes short-term warrants to purchase up to 14,444,446 additional shares, which could generate up to $6.5 million in additional proceeds if fully exercised.

The warrants will be exercisable at $0.45 per share upon stockholder approval and will expire after three years. The offering, expected to close around May 27, 2025, is being managed by H.C. Wainwright & Co. as exclusive placement agent, with Brookline Capital Markets as financial advisor. The company plans to use the proceeds for working capital and general corporate purposes.

IMUNON (NASDAQ: IMNN) has announced groundbreaking results from its Phase 2 OVATION 2 Study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The study demonstrated a 13-month increase in median overall survival (46 vs. 33 months) and a 3-month improvement in progression-free survival (14.9 vs. 11.9 months) compared to standard care.

Notably, patients receiving PARP inhibitors alongside IMNN-001 showed exceptional results, with median overall survival not yet reached after 5+ years versus 37 months in the control group. The therapy was well-tolerated with no serious immune-related adverse events. Based on these promising results, IMUNON has initiated its pivotal Phase 3 OVATION 3 Study at two sites.

The findings will be presented at the 2025 ASCO Annual Meeting and published in Gynecologic Oncology.

IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, has announced the withdrawal of its Form S-1 Registration Statement (No. 333-286403) with the SEC. The registration statement, originally filed on April 4, 2025, was withdrawn as the company has decided not to proceed with the planned public offering at this time. The statement had not been declared effective by the SEC, and no securities were sold in connection with the offering.

IMUNON announced promising 6-month data from its Phase 1 trial of IMNN-101, a DNA plasmid vaccine using their PlaCCine® platform for COVID-19 protection. The trial, involving 24 healthy volunteers, showed durability of protection with up to 3-fold median increase in neutralizing antibodies at 6 months post-single dose. The highest dose cohorts (2.0mg and 1.0mg) demonstrated stronger immune responses compared to the 0.5mg cohort, with some participants showing up to 8-fold increases. The vaccine targets the SARS-CoV-2 Omicron XBB1.5 variant and showed cross-reactivity against newer variants. IMNN-101 demonstrated key advantages over mRNA vaccines, including better temperature stability and easier manufacturing. The vaccine maintained its safety profile with no serious adverse effects reported.